Biogen Stock Soars Following U-turn with their Alzheimer Drug Plans
By Rajaneesh K. Gopinath, Ph.D. Last March, Biogen and its partner Eisai had announced their decision to discontinue a couple of late stage clinical trials of aducanumab, an investigational human monoclonal antibody. …
Read More